Hvsen Biotech is a listed company on the Chinese stock market (Stock code: 300871), which focuses on the animal health business. Our business covers the research, production, and sales of Farm Anima medicines, APIs, pet medicines, and pet supplements.
Hvsen revenue continues to grow steadily, and the annual revenue of 2024 is over $200 million.
Hvsen Biotech is:
The top 1 pig medicine producer in China.
Top 10 animal medicine producers in China.The biggest Tylvalosin Tartrate APl producer in the world (Hubei Hvsen), A leading pet medicine research and production company in China.